Analgesic Efficacy of Adding Sciatic Blockade to the 3-in-1 Block Following Total Knee Arthroplasty: A Meta-analysis
AuthorHolmes, Johnnie M.
MetadataShow full item record
AbstractBackground: Total knee arthroplasty (TKA) is one of the most common orthopedic procedures performed. It is also invasive and is associated with severe postoperative pain. The 3-in-1 block has been repeatedly demonstrated to provide effective postoperative analgesia. However, adding sciatic blockade to the 3-in-1 has become a growing practice as a result of residual pain to the posterior knee, although the additional benefit is unknown particularly in light of the potential risks. Purpose: To examine the analgesic efficacy and associated adverse events of adding sciatic blockade to the 3-in-1 block compared to the 3-in-1 alone for postoperative analgesia following TKA. Methods: A meta-analysis was conducted on relevant articles from 1993 to 2010. Methodological rigor was applied to each of the analytical procedures including: evaluation of between-study heterogeneity, pooling effects, subgroup analyses, sensitivity analysis, and assessment of publication bias. Results: Nine studies representing 1827 subjects were included. Pain outcomes were measured with the visual analog scale both at rest (VASr) and dynamic (VASd) and reported as the weighted mean difference (WMD). The addition of sciatic blockade demonstrated improved postoperative analgesia with the greatest effects up to 24 hours postoperatively: early (6-8hr) VASr WMD -2.039 (95% CI: -2.718, -1.360); 12hr VASr WMD -1.491 (95% CI: -2.174, -0.808); 24hr VASr WMD -0.767 (95% CI: -1.114, -0.421); 24hr VASd WMD -0.671 (95% CI: -1.301, -0.041). The 24hr opioid consumption was also lower [WMD -10.237 (95% CI: -20.029, -0.444)]. After 24 hours, effects were small and/or not significant. There was also a statistically significant advantage in maximum knee flexion on POD3 [WMD -7.102 (95% CI: -11.864, -2.339)]. A lack of consistent reporting precluded quantitative analysis on adverse events. Conclusion: Findings support the use of peripheral nerve blocks for postoperative analgesia following TKA. The addition of sciatic blockade appears to offer greater analgesic efficacy than a 3-in-1 block alone but only in the early postoperative period. However, until an accurate estimate of associated adverse events can be unveiled, the addition of a sciatic block cannot be recommended for all patients following TKA. It should, however, be considered in the postoperative period for those patients who continue to experience substantial pain to the posterior aspect of the knee on a case-by-case basis.
DescriptionUniversity of Maryland, Baltimore. Nursing. Ph.D. 2010
Keyword3-in-1 nerve block
femoral nerve block
peripheral nerve block
sciatic nerve block
total knee arthroplasty
Arthroplasty, Replacement, Knee
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/894
Showing items related by title, author, creator and subject.
Characterization of novel retinoic acid metabolism blocking agents (RAMBAs) in breast cancer model systemsPatel, Jyoti B.; Njar, Vincent (2005)All-trans-retinoic acid (ATRA) and other retinoids, potent modulators of a variety of important cellular functions are effective in prevention and therapy of many cancers including breast cancer. Increased metabolism of ATRA by ATRA inducible cytochrome P450 enzymes present in different cells including cancer cells is one of the reasons for the emergence of ATRA resistance and hampering its clinical use. Additionally, high therapeutic doses of ATRA have adverse effects and are not recommended.Retinoic acid metabolism blocking agents (RAMBAs) prevent rapid metabolism of ATRA. Use of RAMBAs is an emerging approach to increase the endogenous levels and thus potentiate the effect of ATRA without administering high exogenous doses. The objective of this project was to investigate the in vitro and in vivo role of novel C-4 azolyl RAMBAs rationally developed in our laboratory, against breast cancer; determine how they would potentiate the effectiveness of ATRA as well as study the molecular mechanisms involved. Novel RAMBAs (VN/14-1, VN/50-1, VN/66-1 and VN/69-1), structural analogs of ATRA/13-cis-retinoic acid, inhibited ATRA metabolism in hormone dependent MCF-7 cells and T47D cells; and microsomes with IC50 values in nanomolar range as determined by HPLC analysis. RAMBAs (0.0001--10 muM) had dose dependent antiproliferative action, suggesting that they have retinoidal activity as well. VN/50-1 and VN/14-1 enhanced ATRA's antiproliferative action in MCF-7 cells. RAMBAs induced differentiation in these cell lines as determined by analysis of differentiation markers cytokeratin 8/18 and E-cadherin. Induction of apoptosis by RAMBAs was determined by TUNEL assay and Western blotting of apoptosis related proteins. Cell cycle analysis indicated that RAMBAs arrest cells in the G1 phase and reduce cells in the S phase. RAMBAs reduced the expression of Cyclin D1 in these cell lines. VN/14-1 like ATRA increased the expression of estrogen receptor-alpha in MCF-7 cells. VN/14-1 besides being a potent RAMBA, has pleiotropic role, is well tolerated and significantly suppressed MCF-7 tumor growth (∼90.35% vs. control, p < 0.0005; at 66.0 mumole/kg/day dose) in female ovariectomized nude mice. Promising RAMBAs endowed with multiple biological activities should be suitable for further clinical investigations for chemoprevention and therapy of breast cancer.
Retinoids and retinoic acid metabolism blocking agents in combination with histone deacetylase inhibitors for prostate cancer therapyKhandelwal, Aakanksha; Njar, Vincent (2007)All-trans-retinoic acid (ATRA), a metabolite of vitamin A, is 5 to 8 times lower in prostate carcinoma tissue when compared to a normal prostate and benign prostatic hyperplasia. ATRA plays a major role in a number of biological processes and is metabolized by cytochrome P450 enzymes into inactive polar metabolites. The anticancer effects of a novel class of agents called atypical retinoic acid metabolism blocking agents (RAMBAs) were examined in combination with histone deacetylase inhibitors (HDACIs). The purpose of this study was to select combinations of agents which would have potent anti-cancer activities in a hormone insensitive prostate cancer model. One particular RAMBA, VN/66-1 which displays favorable pharmacokinetics and minimal toxicity was found to be highly potent in inhibiting PC-3 cell growth. Two HDACIs, SAHA and MS-275 were also found to be potent in inhibiting PC-3 cell viability. The combinations of VN/66-1 + MS-275 and VN/66-1 + SAHA synergistically inhibited PC-3 cell growth caused cytotoxicity/cytostaticity. Treatment of PC-3 xenografts with VN/66-1 (10 mg/kg/day) + MS-275 (2.5 mg/kg/day) for 18 days resulted in an 85% reduction in final mean tumor volume compared with control. The combination of VN/66-1 + SAHA, however, did not reduce tumor growth as effectively as the two agents individually most likely due to too low doses. The data obtained suggest that the mechanism of action of the combination of VN/66-1 + MS-275 is through apoptosis and DNA damage-induced p21 WAF1/CIP1 activation. Active p21 is involved in the inhibition of the cdc2-cyclin B1 complex resulting in eventual G2/M phase arrest. This induction of p21 is also in part due to the enhancement of acetylation of histones H3 and H4 which is also responsible for the activation of tumor suppressor gene RARbeta2, the latter which also plays a role in mediating cell death. Up-regulation of Bad and down-regulation of Bcl-2 as well as PARP cleavage indicated that apoptosis via the intrinsic pathway is also contributing to cell death. Together, these results suggest that VN/66-1 or its combination with MS-275 may be a novel therapy for the treatment of hormone refractory prostate carcinoma.
Mechanisms of Action and Efficacy Modulation of Novel Retinoic Acid Metabolism Blocking Agent (RAMBA) VN/12-1 in Estrogen Receptor-α Negative Breast Cancer Model Systems: Targeting AutophagyGodbole, Abhijit Moreshwar; Njar, Vincent (2011)Breast cancer (BC) is the most common cancer and the second leading cause of cancer related deaths among women in the United States. Despite important advances in treatment, breast cancer remains incurable due to the emergence of alternative pathways adopted by cancer cells to overcome the effects of anti-cancer therapy. This molecular heterogeneity in the cellular response to anti-cancer therapy challenges the development of effective therapeutic strategies. To overcome this issue, a rational approach would be to concomitantly target clinically relevant cellular abnormalities with combination therapy or to use a potent multi-targeted agent. Autophagy is a critical physiological process of cancer cell survival in the presence of chemotherapeutic stress and is an important cause of resistance to anti-cancer therapy. Drugs that inhibit autophagy e.g. chloroquine-(CHL) deprive the cells of this protective mechanism and therefore are promising agents in combination chemotherapy of breast cancer. All-trans retinoic acid (ATRA), a potent differentiation inducing agent, has been tested as anticancer agent for a number of cancers including breast cancer, but its rapid metabolism to inactive metabolites is a major problem in its clinical use. VN/12-1, a novel retinoic acid metabolism blocking agent (RAMBA) developed in our laboratory, showed improved anti-proliferative activity over ATRA against estrogen receptor α (ER-α) positive and negative breast cancer cell lines. Human epidermal growth factor receptor-2 (Her-2) is a critical protein involved cell proliferation and metastasis. Her-2 has been involved in increasing the frequency of tumor stem cells and it has also been implicated in the development of drug resistance. Hence, for our current studies, we primarily focused on a cell line which is deficient in ER-α and which overexpresses Her-2 (SKBR-3 cells). We showed here that VN/12-1 inhibits G1-S phase cell cycle transition. However, short treatment of VN/12-1 induced autophagy in these cells and protected cells from apoptosis. VN/12-1-induced autophagy was preceded by ER stress (ERS). We further demonstrated that suppression of autophagy using either pharmacological inhibitors or RNA interference of Beclin-1 enhanced cell death induced by VN/12-1 in SKBR-3 cells. The combination of VN/12-1with autophagy inhibitor - CHL resulted in synergistic effects in that it enhanced apoptosis in vitro and in vivo which was caspase dependent. Importantly, VN/12-1 (5 mg/kg twice weekly) and VN/12-1 (5 mg/kg twice weekly) + chloroquine (50 mg/kg twice weekly) significantly suppressed established SKBR-3 tumor growth by 81.4% (p < 0.001 vs. control) and 96.2% (p < 0.001 vs control), respectively without incurring overt signs of toxicity or significant loss of body weight. Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of RAMBAs in the treatment of breast cancer. It is hoped that this combination therapy would solve the problem of the development of acquired resistance due to autophagy that typically follows the chemotherapeutic treatment of breast cancer. We envision further advanced preclinical development of this combination therapy as potential therapy for breast cancer.